Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2013

01-06-2013 | Original Article

The relationship between urinary bisphenol A levels and meningioma in Chinese adults

Authors: Bo Duan, Xuebin Hu, Hongyang Zhao, Jun Qin, Jie Luo

Published in: International Journal of Clinical Oncology | Issue 3/2013

Login to get access

Abstract

Background

Estrogen has been implicated as a risk factor for meningioma. Bisphenol A (BPA), a widely used synthetic xenoestrogen, has already been reported to be associated with several estrogen-sensitive tumors.

Method

An exploratory association study of 243 meningioma cases and 258 frequency-matched healthy controls was conducted, using subjects from a hospital-based study to demonstrate the association of urine BPA concentration and the risk of meningioma. The specimens and data of patients were collected at Union Hospital, Wuhan, China, from 2009 to 2010.

Results

A positive association between increasing levels of urinary BPA and meningioma was observed, independent of confounding factors such as gender, age, race, body mass index, HRT use, BMI, and family history of cancer. Compared to quartile 1 (referent), the multivariate-adjusted odds ratio of meningioma associated with quartile 4 was 1.45 (95 % CI, 1.02–1.98) (P trend = 0.03).

Conclusion

In this case–control study from China, a clear association between urinary BPA concentrations and diagnosis of meningioma was detected.
Literature
1.
go back to reference Longstreth WT, Dennis LK, McGurire VM et al (1993) Epidemiology of intracranial meningioma. Cancer (Phila) 72:639–648CrossRef Longstreth WT, Dennis LK, McGurire VM et al (1993) Epidemiology of intracranial meningioma. Cancer (Phila) 72:639–648CrossRef
2.
go back to reference Sadetzki S, Flint-Richter P, Ben-Tal T et al (2002) Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 97:1078–1082PubMedCrossRef Sadetzki S, Flint-Richter P, Ben-Tal T et al (2002) Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 97:1078–1082PubMedCrossRef
3.
go back to reference Alexiou GA, Markoula S, Gogou P et al (2011) Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 113:261–267PubMedCrossRef Alexiou GA, Markoula S, Gogou P et al (2011) Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 113:261–267PubMedCrossRef
5.
go back to reference Roelvink NC, Kamphorst W, van Alphen HA et al (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44:209–215PubMedCrossRef Roelvink NC, Kamphorst W, van Alphen HA et al (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44:209–215PubMedCrossRef
6.
go back to reference Schoenberg BS, Christine BW, Whisnant JP (1975) Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25:705–712PubMedCrossRef Schoenberg BS, Christine BW, Whisnant JP (1975) Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25:705–712PubMedCrossRef
7.
go back to reference Carroll RS, Zhang J, Black PM (1999) Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 42:109–116PubMedCrossRef Carroll RS, Zhang J, Black PM (1999) Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 42:109–116PubMedCrossRef
8.
go back to reference Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113–120PubMedCrossRef Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113–120PubMedCrossRef
9.
go back to reference Speirs V, Boyle-Walsh E, Fraser WD (1997) Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. Int J Cancer 72:714–719PubMedCrossRef Speirs V, Boyle-Walsh E, Fraser WD (1997) Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. Int J Cancer 72:714–719PubMedCrossRef
10.
go back to reference Michaud DS, Gallo V, Schlehofer B et al (2010) Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev 19:2562–2569PubMedCrossRef Michaud DS, Gallo V, Schlehofer B et al (2010) Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev 19:2562–2569PubMedCrossRef
12.
go back to reference Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 26:279–282PubMedCrossRef Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 26:279–282PubMedCrossRef
13.
go back to reference Claus EB, Black PM, Bondy ML et al (2007) Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer (Phila) 110:471–476CrossRef Claus EB, Black PM, Bondy ML et al (2007) Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer (Phila) 110:471–476CrossRef
14.
go back to reference Calafat AM, Ye X, Wong LY et al (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environ Health Perspect 116:39–44PubMedCrossRef Calafat AM, Ye X, Wong LY et al (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environ Health Perspect 116:39–44PubMedCrossRef
15.
go back to reference Rubin BS (2011) Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol 127:27–34PubMedCrossRef Rubin BS (2011) Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol 127:27–34PubMedCrossRef
16.
go back to reference Kundakovic M, Champagne FA (2011) Epigenetic perspective on the developmental effects of bisphenol A. Brain Behav Immun 25:1084–1093PubMedCrossRef Kundakovic M, Champagne FA (2011) Epigenetic perspective on the developmental effects of bisphenol A. Brain Behav Immun 25:1084–1093PubMedCrossRef
17.
go back to reference Wolstenholme JT, Rissman EF, Connelly JJ (2010) The role of bisphenol A in shaping the brain, epigenome and behavior. Horm Behav 59:296–305PubMedCrossRef Wolstenholme JT, Rissman EF, Connelly JJ (2010) The role of bisphenol A in shaping the brain, epigenome and behavior. Horm Behav 59:296–305PubMedCrossRef
18.
go back to reference Okada H, Tokunaga T, Liu X et al (2008) Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environ Health Perspect 116:32–38PubMedCrossRef Okada H, Tokunaga T, Liu X et al (2008) Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environ Health Perspect 116:32–38PubMedCrossRef
19.
go back to reference Matsushima A, Kakuta Y, Teramoto T et al (2007) Structural evidence for endocrine disruptor bisphenol A binding to human nuclear receptor ERR gamma. J Biochem 142:517–524PubMedCrossRef Matsushima A, Kakuta Y, Teramoto T et al (2007) Structural evidence for endocrine disruptor bisphenol A binding to human nuclear receptor ERR gamma. J Biochem 142:517–524PubMedCrossRef
20.
go back to reference Melzer D, Harries L, Cipelli R et al (2011) Bisphenol A exposure is associated with in vivo estrogenic gene expression in adults. Environ Health Perspect 127:27–34 Melzer D, Harries L, Cipelli R et al (2011) Bisphenol A exposure is associated with in vivo estrogenic gene expression in adults. Environ Health Perspect 127:27–34
21.
go back to reference Soto AM, Vandenberg LN, Maffini MV et al (2008) Does breast cancer start in the womb? Basic Clin Pharmacol Toxicol 102:125–133PubMedCrossRef Soto AM, Vandenberg LN, Maffini MV et al (2008) Does breast cancer start in the womb? Basic Clin Pharmacol Toxicol 102:125–133PubMedCrossRef
22.
go back to reference Henderson BE, Bernstein L, Ross RK et al (1988) The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57:216–218PubMedCrossRef Henderson BE, Bernstein L, Ross RK et al (1988) The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57:216–218PubMedCrossRef
23.
go back to reference Powell IJ, Meyskens FL (2001) African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology 57:178–181PubMedCrossRef Powell IJ, Meyskens FL (2001) African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology 57:178–181PubMedCrossRef
24.
go back to reference Timms BG, Howdeshell KL, Barton L et al (2005) Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc Natl Acad Sci USA 102:7014–7019PubMedCrossRef Timms BG, Howdeshell KL, Barton L et al (2005) Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc Natl Acad Sci USA 102:7014–7019PubMedCrossRef
25.
go back to reference Ho SM, Tang WY, Belmonte de Frausto J et al (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 66:5624–5632PubMedCrossRef Ho SM, Tang WY, Belmonte de Frausto J et al (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 66:5624–5632PubMedCrossRef
26.
go back to reference Lang IA, Galloway TS, Scarlett A et al (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300:1303–1310PubMedCrossRef Lang IA, Galloway TS, Scarlett A et al (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300:1303–1310PubMedCrossRef
27.
go back to reference Gazzeri R, Galarza M, Gazzeri G (2007) Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 357:2411–2412PubMedCrossRef Gazzeri R, Galarza M, Gazzeri G (2007) Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 357:2411–2412PubMedCrossRef
28.
go back to reference Jay JR, MacLaughlin DT, Riley KP et al (1985) Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 62:757–762PubMedCrossRef Jay JR, MacLaughlin DT, Riley KP et al (1985) Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 62:757–762PubMedCrossRef
29.
go back to reference Vandenberg LN, Maffini MV, Sonnenschein C et al (2009) Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev 30:75–95PubMedCrossRef Vandenberg LN, Maffini MV, Sonnenschein C et al (2009) Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev 30:75–95PubMedCrossRef
30.
go back to reference Calafat AM, Kuklenyik Z, Reidy JA et al (2005) Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect 113:391–395PubMedCrossRef Calafat AM, Kuklenyik Z, Reidy JA et al (2005) Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect 113:391–395PubMedCrossRef
31.
go back to reference Hiroi H, Tsutsmi O, Momoeda M et al (1999) Differential interactions of bisphenol A and 17-beta-estradiol with estrogen receptor alpha (ER-alpha) and ER-beta. Endocr J 46:773–778PubMedCrossRef Hiroi H, Tsutsmi O, Momoeda M et al (1999) Differential interactions of bisphenol A and 17-beta-estradiol with estrogen receptor alpha (ER-alpha) and ER-beta. Endocr J 46:773–778PubMedCrossRef
32.
go back to reference Matthews JB, Twomey K, Zacharewski TR (2001) In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. Chem Res Toxicol 14:149–157PubMedCrossRef Matthews JB, Twomey K, Zacharewski TR (2001) In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. Chem Res Toxicol 14:149–157PubMedCrossRef
33.
go back to reference Lewis JB, Lapp CA, Schafer TE et al (2000) 4-Hydroxytamoxifen-induced cytotoxicity and bisphenol A: competition for estrogen receptors in human breast cancer cell lines. In Vitro Cell Dev Biol Anim 36:320–326PubMedCrossRef Lewis JB, Lapp CA, Schafer TE et al (2000) 4-Hydroxytamoxifen-induced cytotoxicity and bisphenol A: competition for estrogen receptors in human breast cancer cell lines. In Vitro Cell Dev Biol Anim 36:320–326PubMedCrossRef
34.
go back to reference Lapensee EW, Tuttle TR, Fox SR et al (2009) Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells. Environ Health Perspect 117:175–180PubMed Lapensee EW, Tuttle TR, Fox SR et al (2009) Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells. Environ Health Perspect 117:175–180PubMed
35.
go back to reference Rubin BS, Soto AM (2009) Bisphenol A: perinatal exposure and body weight. Mol Cell Endocrinol 304:55–62PubMedCrossRef Rubin BS, Soto AM (2009) Bisphenol A: perinatal exposure and body weight. Mol Cell Endocrinol 304:55–62PubMedCrossRef
36.
go back to reference Newbold RR, Padilla-Banks E, Jefferson WN (2009) Environmental estrogens and obesity. Mol Cell Endocrinol 304:84–89PubMedCrossRef Newbold RR, Padilla-Banks E, Jefferson WN (2009) Environmental estrogens and obesity. Mol Cell Endocrinol 304:84–89PubMedCrossRef
37.
go back to reference Shankar A, Teppala S (2011) Relationship between urinary bisphenol A levels and diabetes mellitus. J Clin Endocrinol Metab 15:3455–3462 Shankar A, Teppala S (2011) Relationship between urinary bisphenol A levels and diabetes mellitus. J Clin Endocrinol Metab 15:3455–3462
38.
go back to reference Benson VS, Pirie K, Green J et al (2008) Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 99:185–190PubMedCrossRef Benson VS, Pirie K, Green J et al (2008) Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 99:185–190PubMedCrossRef
39.
go back to reference Jhawar BS, Fuchs CS, Colditz GA et al (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853PubMedCrossRef Jhawar BS, Fuchs CS, Colditz GA et al (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853PubMedCrossRef
40.
go back to reference Michaud DS, Bove G, Gallo V et al (2011) Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study. Cancer Prev Res (Phila) 4:1385–1392CrossRef Michaud DS, Bove G, Gallo V et al (2011) Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study. Cancer Prev Res (Phila) 4:1385–1392CrossRef
Metadata
Title
The relationship between urinary bisphenol A levels and meningioma in Chinese adults
Authors
Bo Duan
Xuebin Hu
Hongyang Zhao
Jun Qin
Jie Luo
Publication date
01-06-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-012-0408-6

Other articles of this Issue 3/2013

International Journal of Clinical Oncology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine